» Authors » G Johan A Offerhaus

G Johan A Offerhaus

Explore the profile of G Johan A Offerhaus including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 166
Citations 7318
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
21.
Hackeng W, Morsink F, Moons L, Heaphy C, Offerhaus G, Dreijerink K, et al.
Diagn Cytopathol . 2019 Dec; 48(4):308-315. PMID: 31846235
Background: The transcription factors ARX and PDX1, and alternative lengthening of telomeres (ALT) were recently described as prognostic markers for resected non-functional pancreatic neuroendocrine tumors (PanNETs). ALT positive tumors with...
22.
Driehuis E, Van Hoeck A, Moore K, Kolders S, Francies H, Gulersonmez M, et al.
Proc Natl Acad Sci U S A . 2019 Dec; 116(52):26580-26590. PMID: 31818951
We report the derivation of 30 patient-derived organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical of...
23.
Backes Y, Seerden T, van Gestel R, Kranenburg O, Ubink I, Schiffelers R, et al.
Gastroenterology . 2019 Aug; 157(5):1222-1232.e4. PMID: 31419435
Background And Aims: In patients who have undergone surgery for colorectal cancer (CRC), 3% have recurrence of (metachronous) CRC. We investigated whether tumor seeding during colonoscopy (iatrogenic implantation of tumor...
24.
Noe M, Hackeng W, de Leng W, Vergeer M, Vleggaar F, Morsink F, et al.
Am J Surg Pathol . 2019 Jul; 43(9):1297-1302. PMID: 31261289
Germline mutations in CDKN2A result in Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM), which is associated with an increased risk for pancreatic ductal adenocarcinoma and melanoma. CDKN2A is somatically inactivated...
25.
Kryklyva V, Haj Mohammad N, Morsink F, Ligtenberg M, Offerhaus G, Nagtegaal I, et al.
Cancer Biol Ther . 2019 Apr; 20(7):949-955. PMID: 31002019
Acinar cell carcinoma (ACC) is a rare pancreatic neoplasm with dismal prognosis. Insights into the molecular basis of ACC can pave the way for the application of more effective, personalized...
26.
Hruban R, Gaida M, Thompson E, Hong S, Noe M, Brosens L, et al.
J Pathol . 2019 Mar; 248(2):131-141. PMID: 30838636
The remarkable aggressiveness of pancreatic cancer has never been fully explained. Although clearly multifactorial, we postulate that venous invasion, a finding seen in most pancreatic cancers but not in most...
27.
Hackeng W, de Guerre L, Kuypers K, Snoek A, Morsink F, Offerhaus G, et al.
Pancreas . 2018 Dec; 48(1):135-138. PMID: 30531244
We report a case of pseudomyxoma peritonei (PMP) arising in a 62-year-old male patient with Lynch syndrome (LS). The patient's medical history included an adenocarcinoma of the colon for which...
28.
Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, et al.
Ann Surg . 2018 Oct; 271(3):566-573. PMID: 30339629
Objective: The aim of this study was to investigate the key molecular alterations in small primary pancreatic neuroendocrine tumors (PanNETs) associated with the development of liver metastases. Background: Well-differentiated PanNETs...
29.
Kessels K, Backes Y, Elias S, van den Blink A, Offerhaus G, van Bergeijk J, et al.
Clin Gastroenterol Hepatol . 2018 Aug; 17(6):1112-1120.e1. PMID: 30130623
Background & Aims: Risk stratification for adverse events, such as metastasis to lymph nodes, is based only on histologic features of tumors. We aimed to compare adverse outcomes of pedunculated...
30.
Luchini C, Cros J, Pea A, Pilati C, Veronese N, Rusev B, et al.
Hum Pathol . 2018 Jul; 81:157-165. PMID: 30031096
Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that...